Embark
Develop foundational knowledge to support launch in a new therapy area or new asset
When you have an asset in a treatment area which is new to you or in a disease area which is currently untreated, you might not know much about the patient, their needs and behaviors or about their journey.
Our foundational research can be used to gather initial insights about patients' unmet needs and identify any roadblocks in the patient journey.
To help understand patient journey in an unfamiliar therapy area
Or for a new asset in development
A starting point for future research and strategy
The types of questions we would ask at this stage of research include:
Who are the stakeholders in the journey?
How do patients get introduced to healthcare system?
What are the touchpoints in the journey?
What are the triggers for treatment?
What are the treatment algorithms?
What are the emotional and cognitive drivers during this part of the journey
Living With is a series of reports based on quantitative and qualitative primary market research with patients which offer comprehensive and cost-effective insight into the patient journey.Find out more here
Our Embark approach was used to understand the patient journey for a previously untreated rare disease.
Our client needed to research an extremely small and difficult to reach audience in multiple markets across the globe in support of their new product in development.
We created a market research online community platform to run across multiple markets for a year. Participants were able to access the platform throughout the study from a variety of devices, including mobile, and take part in scheduled polls, mini-surveys and discussions. In addition we were able to field spontaneous client questions, based on the previous responses and stakeholder needs which arose throughout the study.
The platform offered the functionality for participants to provide open ended responses and upload photos and videos, which provided the client with qualitative emotional insights. The platform also enabled us to provide a broad range of quantitative analyses of the community.
Longitudinal analysis told the story of the respondents' journey, the barriers they faced and opportunities for pharma using individual “moments-of-truth”. Not only could we show the patient’s journey and pathway, we also elicited deep emotional insights from the participants, as they discussed the stages of their journey and relationship with their HCPs.
